Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
about
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisRenal cell cancer: overview of the current therapeutic landscape.Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.Molecular mechanisms of resistance to tumour anti-angiogenic strategiesEfficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureDevelopment of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.Advances in renal cell carcinoma treatment.Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.Current status of targeted therapy for advanced renal cell carcinomaEverolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysisA multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinomaOutcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapiesPresent and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.Meta-analysis of dermatological toxicities associated with sorafenib.Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.Sunitinib malate for the treatment of renal cell carcinoma.Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.Second-line systemic therapy for the treatment of metastatic renal cell cancer.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatmentSequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Second-line treatment for renal cell cancer.Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.
P2860
Q27003304-383CDD8F-F0C2-4793-8777-1AC80EE2DED3Q30248354-4B13F2E6-4FB1-4395-B138-436612CA75C6Q33606102-AA869C7F-8A07-48B9-B366-06F159AB7E5DQ33633424-316312F4-4F98-434A-9C6F-591A6CECAB97Q33652827-E40B34A2-6D6C-4637-9905-BF43B2111127Q33718025-7D62FC1F-1785-4929-8A24-0CFC967CE90CQ33737641-615FE2BC-A641-4253-A15C-73CADC323E98Q33770680-E9D39BB3-CF7C-4F2C-B269-931539EE9B53Q34206601-F772081D-33D3-4DE5-9A51-5D13241CAE33Q34300621-4A4B7640-61D9-4E34-875B-B3E7401B0E1FQ34554398-3BAB15F2-197F-4E9A-A20F-215459AAEDFDQ34658095-DAC4C28D-0F07-4034-8EC4-3A918A207227Q34779020-0EBAF2B7-84BA-4859-BD30-F9749DC7D325Q35076407-88631E2F-6E81-4EC6-9ACE-BF87C4372311Q35583953-15DFD1DF-6AA2-4CCB-B1E0-41D1C40845B1Q35903850-5DC1C1F2-8955-43F2-B53C-3A6E49924639Q35927136-ABDD812E-0253-403B-B066-0E77E847802CQ35947955-D5ADDBF4-F037-4F81-B99B-33C5A7523BA6Q37283720-115D39BD-F381-4822-8643-C4E075D2CAF5Q37438970-0E502EAD-2D4C-4A7B-AC0F-12206B29F631Q37838448-ADB6D4B9-EEF9-48E1-A76E-C86B324F0223Q37866796-932A5BBE-6053-4D7A-B9A0-7FD9CDB9D49EQ37867169-9903F28F-84C6-4F4D-9C71-A4D2DB76C7B9Q37898560-54BE3416-130E-4C27-902A-2E4A2CF894E6Q37997462-F5E99D54-0F70-4785-AF86-6ACB39844A41Q38011201-2E9F09ED-585C-4952-9809-0452853F9D30Q38016794-327C017B-F41C-4C49-95BA-E630372B6118Q38020244-C5E93406-4D82-4EE3-B497-1B626AAE3273Q38025626-A7A07BEE-294B-41EB-A566-0364837B4404Q38068584-9E842B78-D1C8-4DA0-9766-1D883E088F89Q38095926-D8A2125B-FBAB-4FCB-982A-7273299815DBQ38103397-BB2F3CC4-D085-4735-BFDE-47988165F273Q38188423-A9CE7ABF-8165-4994-9D59-291B3E4FCCC4Q38189898-58414401-03C3-4406-8F6E-72D5907E85ACQ39008859-40B3EDEE-B8C4-4636-BD7E-A0F95CAD8698Q42551794-68814B77-0473-46F8-9C73-152EA6FACBB7Q42921533-AA18AEEB-F21D-41A0-AF61-14CD196D3E2AQ44049376-7E4CE199-760D-4144-977B-DBE171CA8E26Q45026359-7576F735-0CA3-423D-8414-FD4E9CA82E91Q46274363-D0C07AE6-1824-44D1-9235-BA5FE3F165D8
P2860
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@en
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@nl
type
label
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@en
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@nl
prefLabel
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@en
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@nl
P2093
P356
P1476
Phase II study of sorafenib in ...... metastatic renal cell cancer.
@en
P2093
Antonio Gonnella
Ciro Imbimbo
Corrado Ficorella
Gianluca Giannarini
Gianni Bruni
Giovannella Palmieri
Giuseppe Di Lorenzo
Marianna Tudini
Michele Aieta
Michele De Laurentiis
P304
P356
10.1200/JCO.2009.22.6480
P407
P577
2009-08-03T00:00:00Z